

Ref: FOI/GS/ID 8971

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

18 March 2024

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Oncology treatments.

*You asked: All questions are shown as received by the Trust.*

*Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:*

- a. CAPOX (Capecitabine with Oxaliplatin)*
- b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)*
- c. Lonsurf (Trifluridine - tipiracil)*
- d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- f. Any other systemic anti-cancer therapy*
- g. Palliative care only*

*Q2. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:*

- a. Atezolizumab (Tecentriq)*
- b. Durvalumab (Imfinzi)*
- c. Nivolumab (Opdivo)*
- d. Pembrolizumab (Keytruda)*
- e. Chemotherapy*
- f. Radiotherapy*
- g. Chemotherapy AND Radiotherapy*

*Q3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:*

- a. Avelumab + Axitinib (Bavencio + Inlyta)*
- b. Cabozantinib (Cometriq)*

- c. *Nivolumab (Opdivo)*
- d. *Nivolumab + Cabozantinib (Opdivo + Cometriq)*
- e. *Nivolumab + Ipilimumab (Opdivo + Yervoy)*
- f. *Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)*

Trust response:

Please find below the results for period 1/11/23-31/01/24.

Q1	
a.	3
b.	1
c.	0
d.	2
e.	0
f.	28
g.	7
Q2.	
a.	2
b.	0
c.	2
d.	10
e.	19
f.	10
g.	5
Q3.	
a.	1
b.	0
c.	2
d.	0
e.	1
f.	4